How New Advisory Board At BioCryst Pharmaceuticals (BCRX) Has Changed Its Investment Story

Simply Wall St.10-13

BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board made up of senior figures in rare disease research, drug development, and clinical strategy to guide pipeline ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2675657803?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-13 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2675657803","market":"sg","top_or_hot":-1,"title":"How New Advisory Board At BioCryst Pharmaceuticals (BCRX) Has Changed Its Investment Story","media":"Simply Wall St.","content":"<div>\n<p>BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board made up of senior figures in rare disease research, drug development, and clinical strategy to guide pipeline ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-advisory-board-at-biocryst-pharmaceuticals-bcrx-has\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How New Advisory Board At BioCryst Pharmaceuticals (BCRX) Has Changed Its Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow New Advisory Board At BioCryst Pharmaceuticals (BCRX) Has Changed Its Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-13 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-advisory-board-at-biocryst-pharmaceuticals-bcrx-has><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board made up of senior figures in rare disease research, drug development, and clinical strategy to guide pipeline ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-advisory-board-at-biocryst-pharmaceuticals-bcrx-has\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-advisory-board-at-biocryst-pharmaceuticals-bcrx-has","article_id":"2675657803","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-advisory-board-at-biocryst-pharmaceuticals-bcrx-has","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2675657803","pubTimestamp":1791905444,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board made up of senior figures in rare disease research, drug development, and clinical strategy to guide pipeline expansion, translational science, and regulatory planning.\nThe group’s experience building rare disease portfolios, advancing first-in-class therapies, and advising on AI and translational platforms gives BioCryst Pharmaceuticals access to high-level operational insight that could influence future R&D...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BCRX":"BioCryst制药","BK4547":"WSB热门概念"},"translate_title":"BioCryst Pharmaceuticals (BCRX) 的新顾问委员会如何改变其投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1.5},"content_text":"BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board made up of senior figures in rare disease research, drug development, and clinical strategy to guide pipeline expansion, translational science, and regulatory planning. The group’s experience building rare disease portfolios, advancing first-in-class therapies, and advising on AI and translational platforms gives BioCryst Pharmaceuticals access to high-level operational insight that could influence future R&D spend, portfolio choices, and development risk management. This article now explores how BioCryst Pharmaceuticals' investment narrative is affected by the new Scientific Advisory Board that is guiding rare disease R&D.  Seize this rare disease moment around BioCryst Pharmaceuticals by scanning a curated 20 high quality undiscovered gems that could be building tomorrow's pipelines before the wider market pays attention.\nAdvertisementBioCryst Pharmaceuticals Investment Narrative Recap To own BioCryst Pharmaceuticals, you need to believe ORLADEYO can keep supporting the business long enough for the rare disease pipeline to matter. The new Scientific Advisory Board speaks directly to that bet, since it is aimed at refining how capital goes into pipeline expansion, external deals and translational science rather than changing the near term sales picture. The key short term catalyst is still execution on ORLADEYO growth, new indications and the transition away from European revenue. The biggest risk is that heavy R&D and business development spend does not translate into future products, especially with rising hereditary angioedema competition and dependence on a single commercial asset. The SAB formation links most closely to BioCryst Pharmaceuticals' push to progress Netherton syndrome and diabetic macular edema programs and to use its balance sheet flexibility for rare disease assets. These directors have deep rare disease, regulatory and AI platform experience, which fits directly with management's plan to turn a single product story into a multi program portfolio. For catalysts, that matters if SAB input improves trial design, regulatory interactions or de-risks in-licensing. It could help the firm decide which Netherton, DME and HAE follow-on projects warrant more capital in a world of negative shareholder equity, high R&D needs and a competitive rare disease market. BioCryst Pharmaceuticals' current loss of $458.0 million is set against analyst expectations for earnings of $131.3 million by 2029. This implies an earnings swing of about $589 million alongside forecast revenue of $930.1 million in the same year and a projected 1.6% yearly revenue growth rate. Uncover why BioCryst Pharmaceuticals' fair value indicates a 155% potential upside to its current price that may not last much longer. NasdaqGS:BCRX 1-Year Stock Price Chart Exploring Other Perspectives One alternative read on BioCryst Pharmaceuticals leans hard into the risk that ORLADEYO concentration and rare disease pricing pressure cap the story. The most cautious analysts were pencilling in revenue of about $699.6 million and earnings of $85.8 million by 2029 before this new SAB was announced. That is far below the consensus path and shows how widely opinions can differ. Use this SAB news as a prompt to compare those pessimistic assumptions with your own, and to explore how views might shift as the advisory board starts to influence the pipeline plan. Explore 3 other BioCryst Pharmaceuticals fair value estimates, including one that suggests it could be worth just $20.73! The Verdict Is Yours Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for BioCryst Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate BioCryst Pharmaceuticals' overall financial health at a glance.  Looking for more investment ideas beyond BioCryst Pharmaceuticals? Once you have a view on BioCryst Pharmaceuticals, it can help to widen the lens and compare it with other opportunities that match your risk tolerance and income goals. The Simply Wall St Screener lets you filter by quality, balance sheet strength, dividend profile and more so you are not relying on a single story.  If capital preservation sits high on your list, start by weighing companies on a 31 resilient stocks with low risk scores that focuses on resilience rather than excitement. For investors hunting for potential mispricings, compare BioCryst Pharmaceuticals with a broader set of 29 high quality undervalued stocks that pair healthier cash flows with more robust balance sheets. If steady income is a priority, scan a group of 8 dividend fortresses that combine higher yields with an emphasis on durability of payouts over time.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioCryst Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2675657803","isCrawlerRequest":true}